• +1-646-491-9876
    • +91-20-67278686

    Search

    Sedation-Pipeline Review H2 2017

    Sedation-Pipeline Review H2 2017

    • Report Code ID: RW0001881467
    • Category Life Sciences
    • No. of Pages 54
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Sedation-Pipeline Review H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Sedation-Pipeline Review H2 2017 provides an overview of the Sedation (Central Nervous System) pipeline landscape.

    Sedation is the depression of irritability or agitation. Symptoms include talk slowly and may slur their speech unable to concentrate feel dizzy slow breathing heart rate blood pressure will be lower. Treatment includes barbiturates and benzodiazepines.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Sedation-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Sedation (Central Nervous System) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.

    The Sedation (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Sedation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Pre-Registration Phase III Phase II Phase I and Preclinical stages are 1 3 1 1 and 3 respectively. Similarly the Universities portfolio in Preclinical stages comprises 1 molecules respectively.

    Sedation (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Sedation (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Sedation (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Sedation (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Sedation (Central Nervous System) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Sedation (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Sedation (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Sedation (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Sedation-Overview
    Sedation-Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Sedation-Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Sedation-Companies Involved in Therapeutics Development
    Drawbridge Pharmaceuticals Pty Ltd
    Jiangsu Hengrui Medicine Co Ltd
    Jiangsu Nhwa Pharmaceutical Corp Ltd
    Paion AG
    Primex Pharmaceuticals Oy
    The Medicines Company
    Therakind Ltd
    Sedation-Drug Profiles
    alphaxalone-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    clonidine hydrochloride-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EL-001-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MDCO-700-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    midazolam hydrochloride-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    propofol-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    remimazolam-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    remimazolam-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Agonize GABA-A for Sedation-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    XK-568b-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Sedation-Dormant Projects
    Sedation-Discontinued Products
    Sedation-Product Development Milestones
    Featured News & Press Releases
    Jun 05 2017 Primex Pharmaceuticals at Euroanesthesia 2017 Next Innovation in the Management of Pediatric Sedation
    Oct 19 2016 Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting
    Oct 05 2016 Primex Files for Marketing Authorization for a pediatric sedative medication
    Sep 22 2016 PAION Remimazolam Phase III Colonoscopy Data to Be Presented at the American College of Gastroenterology 2016 Meeting
    Sep 06 2016 PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China
    Sep 01 2016 Primex Announces Phase II Results of ADV6209 at the 16th World Congress of Anesthesiologists
    Aug 31 2016 Primex Pharmaceuticals Next real innovation in pediatric anesthesia since propofol
    Jun 19 2016 Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy
    Apr 11 2016 Paion Successfully Completes Patient Recruitment In Phase III Study With Remimazolam For Procedural Sedation During Colonoscopy
    Feb 12 2016 Paion US-Patent & Trademark Office Grants Substance Patent For Remimazolam Besylate
    Feb 09 2016 Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment
    Dec 01 2015 PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy
    Oct 14 2015 Paion Receives Positive Feedback From Japanese Authority PMDA About Production Of Remimazolam For Japan
    Aug 11 2015 Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia
    Jun 08 2015 PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Sedation H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products under Development by Universities/Institutes H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Universities/Institutes H2 2017
    Number of Products by Stage and Target H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Sedation-Pipeline by Drawbridge Pharmaceuticals Pty Ltd H2 2017
    Sedation-Pipeline by Jiangsu Hengrui Medicine Co Ltd H2 2017
    Sedation-Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd H2 2017
    Sedation-Pipeline by Paion AG H2 2017
    Sedation-Pipeline by Primex Pharmaceuticals Oy H2 2017
    Sedation-Pipeline by The Medicines Company H2 2017
    Sedation-Pipeline by Therakind Ltd H2 2017
    Sedation-Dormant Projects H2 2017
    Sedation-Discontinued Products H2 2017

    List of Figures

    Number of Products under Development for Sedation H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products by Targets H2 2017
    Number of Products by Stage and Targets H2 2017
    Number of Products by Mechanism of Actions H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Drawbridge Pharmaceuticals Pty Ltd
    Jiangsu Hengrui Medicine Co Ltd
    Jiangsu Nhwa Pharmaceutical Corp Ltd
    Paion AG
    Primex Pharmaceuticals Oy
    The Medicines Company
    Therakind Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//sedation-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//sedation-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//sedation-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments